Teva Pharmaceutical Industries Limited
TEVA · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.27 | 0.01 | -0.19 |
| FCF Yield | 8.22% | 7.21% | 10.29% | 2.67% |
| EV / EBITDA | 8.96 | 18.36 | -31.23 | 6.83 |
| Quality | ||||
| ROIC | -1.63% | 1.30% | -5.04% | 3.08% |
| Gross Margin | 48.74% | 48.25% | 46.72% | 47.83% |
| Cash Conversion Ratio | -1.55 | -2.22 | -0.66 | 1.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.49% | -0.07% | -3.60% | -2.03% |
| Free Cash Flow Growth | 143.43% | -19.19% | 341.53% | -63.01% |
| Safety | ||||
| Net Debt / EBITDA | 3.34 | 10.86 | -20.28 | 4.83 |
| Interest Coverage | -0.32 | 0.42 | -2.36 | 1.93 |
| Efficiency | ||||
| Inventory Turnover | 2.82 | 2.04 | 2.07 | 2.17 |
| Cash Conversion Cycle | 102.09 | 141.67 | 179.71 | 198.05 |